Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
about
Coming of age: the artificial pancreas for type 1 diabetesInsulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience[Fast-acting insulin - new developments towards more flexibility for the patient].Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.Closed-loop for type 1 diabetes - an introduction and appraisal for the generalist.Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.Moving toward the ideal insulin for insulin pumps.Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development.Euglycaemic glucose clamp: what it can and cannot do, and how to do it.A Review of the Current Challenges Associated with the Development of an Artificial Pancreas by a Double Subcutaneous Approach.Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical FormulationPump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes.Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes.Optimal prandial timing of bolus insulin in diabetes management: a review.Bolusing frequency and amount impacts glucose control during hybrid closed-loop.Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.Lispro administered by the QS-M Needle-Free Jet Injector generates an earlier insulin exposure.Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.Artificial Pancreas or Novel Beta-Cell Replacement Therapies: a Race for Optimal Glycemic Control?
P2860
Q26745886-593C362D-49A1-4ABD-9D4F-CB9316923304Q28085428-E26E0E1D-22C4-4E26-9EBE-C4134704D244Q30313628-9B4B1CC0-0581-4906-81E4-B62C00FDA26CQ33571532-5204CC6C-40C5-4AE5-A3B1-0E54A9049CA5Q33658772-E9B754AA-CAC7-4A16-9620-FCF4E0E39B3CQ36258001-607C1DE4-C809-43E5-82CD-7CAF297E7B2CQ36554243-91245FD9-7D82-4EBB-B19D-A7CEEFAFC164Q37575086-D3F922E6-D784-4B38-B5A5-28A6B9930CA5Q37633455-120AC120-489A-4B48-9249-349A96A8A874Q37742600-E9846255-7FDB-4932-B443-3E8DEDFD80F0Q38381201-9024E0ED-8720-457A-B259-A444295BC857Q38578266-7BF43E7E-74E5-46BA-8DCF-65A0BF0FD999Q38631154-A82AD482-5AC7-43D1-99C2-583761B68734Q38675810-A0687CD7-467F-47C6-9237-F48B93C93EDBQ38692387-345F151A-39DE-453D-AAC7-339305436292Q38806457-B916FE0E-078B-4E5A-AAE4-B88069DF01F2Q38871135-51919811-8002-45E1-BED4-198DECA034C2Q39306224-B5459251-FD2B-4CFA-8829-0A70501BB00DQ42655468-E9511FE7-F03A-4331-92A8-1C5BB144A64FQ47226752-0FCE4019-D656-41D5-9E9A-DE896E4AEC42Q47443616-A196ED73-0FF6-4816-999D-A95A254E9E1FQ47721261-5B16CC28-3CEC-486E-B347-20E1199FA98AQ47769561-833F4235-C17E-44A0-8D39-03ABDF5DA2EDQ48326082-3490C939-9497-46F1-A86E-D5ABF1FC03DCQ48361256-2B49ECA3-8A9C-4BB4-A0ED-34CFCD4FD26CQ50054965-90A5FCF3-6477-47C3-BC6E-3E5266BA2915Q51302693-85E86B40-F588-44B2-B4CF-9056B6FAB5E1Q52680124-BB3C8722-DE30-4472-A103-7B3C5005A3DAQ55431482-B5F385C0-525C-4794-9600-602928AD55C8Q58701212-250A39E0-BF82-4D63-AA76-171F8FA5938A
P2860
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 May 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Faster-acting insulin aspart: ...... c effects than insulin aspart.
@en
Faster-acting insulin aspart: ...... c effects than insulin aspart.
@nl
type
label
Faster-acting insulin aspart: ...... c effects than insulin aspart.
@en
Faster-acting insulin aspart: ...... c effects than insulin aspart.
@nl
prefLabel
Faster-acting insulin aspart: ...... c effects than insulin aspart.
@en
Faster-acting insulin aspart: ...... c effects than insulin aspart.
@nl
P2093
P2860
P356
P1476
Faster-acting insulin aspart: ...... c effects than insulin aspart.
@en
P2093
P2860
P304
P356
10.1111/DOM.12468
P577
2015-05-08T00:00:00Z